Treatment, Medication & Supplement Directory
A comprehensive encyclopedia of medicines, chemotherapy protocols, targeted and immune therapies, supplements, Chinese herbal formulas, Traditional Chinese Veterinary Medicine (TCVM) approaches, and supportive-care options used or discussed in canine and feline tumor care. Directory entries explain what each option is, where it may fit, its evidence and safety boundaries, and what to discuss with a veterinarian; they are references, not individualized prescriptions or rankings.

Mitoxantrone in Veterinary Oncology: Infusion and Blood-Count Profile
Mitoxantrone is an intravenous antineoplastic medicine used in selected canine and feline protocols, with infusion, marrow, and gastrointestinal monitoring.
Read more
Gemcitabine in Veterinary Oncology: Limited and Protocol-Specific Evidence
Gemcitabine is an intravenous antimetabolite considered in selected veterinary protocols, where evidence and toxicity must be reviewed for the exact diagnosis.
Read more
Methotrexate in Veterinary Oncology: Interaction and Organ-Safety Review
Methotrexate is a folate-antagonist antimetabolite with selected veterinary uses and clinically important marrow, gastrointestinal, liver, lung, and interaction considerations.
Read more
Cytarabine in Veterinary Cancer Care: Route and Marrow Monitoring
Cytarabine is an antimetabolite used in selected veterinary hematologic or central nervous system protocols, with route- and schedule-specific monitoring.
Read more
Taxane Chemotherapy: Formulation, Infusion, and Evidence Questions
Taxanes disrupt microtubule dynamics, but formulation, infusion reactions, species experience, and veterinary evidence differ enough that product names are not interchangeable.
Read more
Metronomic Chemotherapy: Goal, Evidence, and Handling Boundary
Metronomic therapy uses regularly scheduled cytotoxic medication in selected plans; it remains prescription hazardous-drug treatment and is not simply gentle chemotherapy.
Read more
L-Asparaginase in Lymphoid Cancer Protocols
L-asparaginase is an enzyme-based antineoplastic used in selected lymphoma or leukemia protocols, with hypersensitivity and protocol-timing considerations.
Read more
Named profile Tanovea (Rabacfosadine): FDA-Approved Injectable Canine Lymphoma TherapyRepresentative category illustration – no product packaging is shown.Tanovea (Rabacfosadine): FDA-Approved Injectable Canine Lymphoma Therapy
Rabacfosadine is a canine lymphoma drug whose current official label, patient selection, cumulative risks, and availability must be verified before use.
Read more
Cisplatin in Dogs: Species-Specific and Kidney-Safety Boundary
Cisplatin is a platinum chemotherapy used only in carefully selected veterinary settings; it has major kidney, gastrointestinal, infusion, and species-specific hazards.
Read more
Tyrosine Kinase Inhibitors: A Class-Level Monitoring Framework
Tyrosine kinase inhibitors are not one interchangeable drug class; target profile, label, evidence, dosing, monitoring, and adverse effects differ by product and patient.
Read more
Imatinib in Canine Mast Cell Tumor Care: Extra-Label Evidence Review
Imatinib has published canine mast cell tumor experience but is not interchangeable with veterinary-labeled TKIs and requires specialist, legal, formulation, and evidence review.
Read more
Named profile Masivet (Masitinib): EU/UK-Authorised Targeted Therapy for c-KIT-Mutated Canine Mast Cell TumorsRepresentative category illustration – no product packaging is shown.Masivet (Masitinib): EU/UK-Authorised Targeted Therapy for c-KIT-Mutated Canine Mast Cell Tumors
Masitinib is an oral canine TKI with an EMA veterinary authorization for a defined mast cell tumor setting; the current regional label governs eligibility and monitoring.
Read more